Strategic Review - Urgently Required, page-16

@wubing

The issue with ALT is they believe they have a product that will sell $M's and $M's worth (just like they did with the burette and autoflush) and therefore don't seem to see the cash burn as excessive

That is alright if the product is close to market, has affiliations or agreements with major pharmas or a large cash balance to continue supporting development, but ALT require further capital

The quarterly report is not going to prompt a single person to invest, and at a time they require capital, how are they going to market the next raise ? The last one at 0.8c delivered very little return in terms of sales, and that is the only benchmark investors are given

Now if ALT weren't ignorant of a need for shareholder relations and marketing, and realized that penny stocks thrive on newsflow, then pieces of news such as the WA funding deal, the FDA ruling out mesh and various other items would at least paint a picture of what is developing behind the scenes and perhaps give investors some confidence of follow through sales in coming months

But when you withhold material news, report poor sales figures and then are coming back to the market requiring additional capital on all time lows, what do they expect is about to happen ? Unless fingers are pulled out of proverbials very quickly, I doubt a raise above 0.5c will get away